Form 4: Regulus Therapeutics Director David Baltimore Acquires Shares in Open Market Transaction

Director David Baltimore of Regulus Therapeutics Inc. purchased 19,610 shares of common stock at an average price of $1.06 per share.

Summary

• David Baltimore, a director at Regulus Therapeutics Inc., acquired 19,610 shares of common stock on January 30, 2025.
• The shares were purchased at a weighted average price of $1.06, with individual prices ranging from $0.97 to $1.15.
• Following the transaction, Mr. Baltimore directly owns 22,169 shares of Regulus Therapeutics Inc. common stock.

Sentiment

Score: 6

Explanation: The document is neutral, reporting a standard insider transaction. It is neither particularly positive nor negative.

Positives

• The purchase of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is typical for directors who may buy or sell shares in their company.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.

Key Dates

Keywords

Regulus Therapeutics, David Baltimore, share purchase, insider trading, common stock, director, RGLS